新冠疫苗同时接种在疫苗安全数据链中的安全性
本研究利用疫苗安全数据链(VSD)2020年12月11日至2022年5月21日的新冠疫苗监测数据,描述≥5岁人群新冠基础免疫与其他疫苗同时接种(SV)的频率并评估23种预设健康结局。结果显示同时接种不常见,总体结局发生率与未同时接种者无统计学显著差异,但部分个体结局观察到统计学显著升高的率比,且结局数量少、未进行多重检验校正。
要点
- 新冠疫苗同时接种不常见:第1剂0.7%(8,455,037人),第2剂0.3%(7,787,013人)。
- 同时接种者总体结局发生率为6.5/万人,未同时接种者为6.8/万人,无统计学显著差异。
- 第1剂后「所有同时接种」组阑尾炎RR 2.09(95%CI 1.06-4.13)、惊厥/癫痫RR 2.78(95%CI 1.10-7.06);第2剂后「流感同时接种」组贝尔麻痹RR 2.82(95%CI 1.14-6.97)。
核心结论
- 同时接种新冠疫苗者中观察到的预设健康结局罕见,与未同时接种者相比无统计学显著差异。
研究设计与样本
- 利用VSD的COVID-19疫苗监测数据(2020年12月11日至2022年5月21日),对≥5岁人群描述同时接种频率。
- 采用泊松回归估计率比(RR),比较同时接种与未同时接种者在第1剂后1-21天、第2剂后1-42天的结局率。
主要发现
- 同时接种不常见:第1剂0.7%(8,455,037人),第2剂0.3%(7,787,013人)。
- 最常见的同时接种疫苗为流感、HPV、Tdap和脑膜炎球菌疫苗。
- 同时接种后结局罕见,第1剂和第2剂后共观察到56例结局。
- 同时接种者总体结局发生率为6.5/万人,未同时接种者为6.8/万人,无统计学显著差异。
关键数值与推荐
- 「所有同时接种」组第1剂后阑尾炎RR 2.09(95%CI 1.06-4.13),惊厥/癫痫RR 2.78(95%CI 1.10-7.06)。
- 「流感同时接种」组第2剂后贝尔麻痹RR 2.82(95%CI 1.14-6.97)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 某些个体结局观察到统计学显著校正率比,但结局数量少。
- 未进行多重检验校正。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Safety data on simultaneous vaccination (SV) with primary series monovalent COVID-19 vaccines and other vaccines are limited. We describe SV with primary series COVID-19 vaccines and assess 23 pre-specified health outcomes following SV among persons aged ≥5 years in the Vaccine Safety Datalink (VSD). METHODS: We utilized VSD's COVID-19 vaccine surveillance data from December 11, 2020-May 21, 2022. Analyses assessed frequency of SV. Rate ratios (RRs) were estimated by Poisson regression when the number of outcomes was ≥5 across both doses, comparing outcome rates between COVID-19 vaccinees receiving SV and COVID-19 vaccinees receiving no SV in the 1-21 days following COVID-19 vaccine dose 1 and 1-42 days following dose 2 by SV type received ("All SV", "Influenza SV", "Non-influenza SV"). RESULTS: SV with COVID-19 vaccines was not common practice (dose 1: 0.7 % of 8,455,037 persons, dose 2: 0.3 % of 7,787,013 persons). The most frequent simultaneous vaccines were influenza, HPV, Tdap, and meningococcal. Outcomes following SV with COVID-19 vaccines were rare (total of 56 outcomes observed after dose 1 and dose 2). Overall rate of outcomes among COVID-19 vaccinees who received SV was not statistically significantly different than the rate among those who did not receive SV (6.5 vs. 6.8 per 10,000 persons). Statistically significant elevated RRs were observed for appendicitis (2.09; 95 % CI, 1.06-4.13) and convulsions/seizures (2.78; 95 % CI, 1.10-7.06) in the "All SV" group following dose 1, and for Bell's palsy (2.82; 95 % CI, 1.14-6.97) in the "Influenza SV" group following dose 2. CONCLUSION: Combined pre-specified health outcomes observed among persons who received SV with COVID-19 vaccine were rare and not statistically significantly different compared to persons who did not receive SV with COVID-19 vaccine. Statistically significant adjusted rate ratios were observed for some individual outcomes, but the number of outcomes was small and there was no adjustment for multiple testing.
引用
- Kenigsberg TA, Hanson KE, Klein NP, et al. Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink. Vaccine. 2023. PMID: 37344264. doi:10.1016/j.vaccine.2023.06.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。